Canada markets close in 5 hours 21 minutes

PFE Jun 2023 37.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.5100-0.0100 (-1.92%)
As of 09:37AM EST. Market open.
Full screen
Loading interactive chart...
  • Reuters

    Pfizer partners with Clear Creek Bio to develop oral COVID-19 drug

    Pfizer Inc and Clear Creek Bio Inc on Tuesday announced a collaboration to identify a potential drug candidate and develop a new class of oral treatment against COVID-19, as Pfizer seeks to expand its anti-infective pipeline. Charlotte Allerton, Pfizer's chief scientific officer, said COVID-19 has "the potential to remain a global health concern for years to come".

  • Zacks

    Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab

    Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.

  • Reuters

    UPDATE 1-Britain's health regulator backs COVID vaccine for infants from six months

    Britain's health regulator on Tuesday authorised a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme.